Oxane HD

Small molecule

AAsociación para Evitar la Ceguera en México

Oxane HD is one of 11 small molecule programs targeting Retinal Detachment. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinal DetachmentActive, not recruiting

Retinal DetachmentPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Retinal Detachment

#DrugCompanyPhaseTrials

Azilect

Teva

Approved

1 2

Pred Forte

Novartis

Approved

1 3

Minocin

Avastin

4 5

Lucentis

Roche

Phase 2

1 6

Trexall

Alnylam Pharmaceuticals

Phase 2

1 7

Dextenza

TTufts Medical Center

Approved

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Phase 1

1 9

ONL1204

OONL Therapeutics

Phase 2

1 10

Denufosol Tetrasodium (INS37217)

Merck & Co.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinal Detachment1 trial

Comparison High-density Silicone Oils in Retinal Detachment

Withdrawn·AAsociación para Evitar la Ceguera en México·Phase 2/3·NCT00403702

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oxane HD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxane HD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxane HD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asociación para Evitar la Ceguera en México company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAsociación para Evitar la Ceguera en México

Oxane HD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinal Detachment1 trial

References

Drug Info

Quick Facts

Related News